AbbVie Inc.

ABBV · XNYS

CIK 1551152fmd_1NHYHMQDZV6KTQM2BTSJ9B6P4BManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	25,638	28,216	32,753	33,266	45,804	56,197	58,054	54,318	56,334	61,160
Cost of revenue	5,832	7,042	7,718	7,439	15,387	17,446	17,414	20,415	16,904	18,204
Gross profit	19,806	21,174	25,035	25,827	30,417	38,751	40,640	33,903	39,430	42,956
Research and development	4,385	5,007	10,329	6,407	6,379	6,922	6,510	7,675	12,791	9,096
Selling, general and administrative	5,881	6,295	7,399	6,942	11,299	12,349	15,260	12,872	14,752	14,010
Operating income	9,340	9,545	6,383	12,983	11,363	17,924	18,117	12,757	9,137	15,075
Interest expense	1,047	1,150	1,348	1,784	2,454	2,423	2,230	2,224	2,808	2,893
Interest and investment income	82	146	204	275	174	39	186	540	648	266
Other non-operating income (expense)	(188)	(466)	(18)	(3,006)	(5,614)	(2,500)	(2,448)	(4,677)	(3,240)	(5,793)
Income before taxes	7,884	7,727	5,197	8,426	3,398	12,989	13,477	6,250	3,716	6,597
Income tax expense	1,931	2,418	(490)	544	(1,224)	1,440	1,632	1,377	(570)	2,364
Net income from continuing operations	5,953	5,309	5,687	7,882	4,622	11,549	11,845	4,873	4,286	4,233
Net income	5,953	5,309	5,687	7,882	4,616	11,542	11,836	4,863	4,278	4,226
Net income to common shareholders	5,923	5,283	5,657	7,842	4,556	11,468	11,782	4,820	4,238	4,186